NCT07075627

Withdrawn

A Study to Evaluate the Incidence of Clinically Suspicious L...

Addario Lung Cancer Medical Institute Source

Addario Lung Cancer Medical Institute

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

ALCMI-024

Study Type

observational

Actual enrollment (reported)

0

Locations

1 country

Sites

1

Timeline

Study Start

September 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

September 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

December 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Brief Summary

This is a multi-center observational study in subjects with a diagnosis of small cell lung cancer. Screening and/or medical record review for symptoms associated with Lambert Eaton Myasthenic Syndrome (LEMS) will be conducted.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: withdrawn
Actual enrollment (reported): 0 participants
Study completion date: December 2026
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
July 11, 2025
Actual (reported)
First Posted
July 20, 2025
Actual (reported)
Study Start
September 2025
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
September 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 2026
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated: August 4, 2026
Status Verified: August 2026
Last Update Submitted: August 1, 2026

Conditions

Lambert Eaton Myasthenic Syndrome (LEMS)Small Cell Lung Cancer ( SCLC )

Keywords

SCLCLEMSsmall cell lung cancerlambert eaton myasthenic syndrome

Outcome Measures

Primary Outcomes (1)

Suspicious LEMS
Incidence of clinically suspicious LEMS diagnosis
1 year

Study Arms (1)

SCLC

Diagnosis of SCLC within 1 year of enrollment

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

United States

You may qualify if:

Adult men or women meeting Age of Majority (AOM) at the time of consent

Sponsors & Collaborators

Addario Lung Cancer Medical Institute
Otherlead

Study Sites (1)

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

MeSH Terms

Conditions

Small Cell Lung CarcinomaLambert-Eaton Myasthenic Syndrome

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesMyasthenia GravisParaneoplastic Syndromes, Nervous SystemNervous System NeoplasmsParaneoplastic Syndromes

Study Officials

Jacob Sands, MD
Dana-Farber Cancer Institute
PRINCIPAL INVESTIGATOR
Gilbert Youssef, MD
Dana-Farber Cancer Institute
PRINCIPAL INVESTIGATOR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: CROSS SECTIONAL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 11, 2025

First Posted

July 20, 2025

Study Start

September 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

NCT00994916

Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

Unknown

NCT01373333

Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome

Unknown

NCT00704925

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

Unknown

NCT02012933

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Unknown

NCT07149363

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Phase 2Recruiting

NCT01377922

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Phase 3Completed

Provide voluntary consent to participate in this study, documented via a signed informed Consent Form (ICF)

Any diagnosis of SCLC

Willing to provide clinical and medical information related to his/her cancer diagnoses to the study team as required

Willing to comply with the requirements of the study

You may not qualify if:

Has been diagnosed with non-tumor Lamber-Eaton Myasthenic syndrome (LEMS) \> 1 year prior to the SCLC diagnosis.
Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements

Contact the study team to confirm eligibility.

Autoimmune Diseases of the Nervous System

Nervous System Diseases

Neurodegenerative Diseases

Neuromuscular Junction Diseases

Neuromuscular Diseases

Autoimmune Diseases

Immune System Diseases

Primary Completion

September 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

December 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated

August 4, 2026

Record last verified: 2026-08

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07075627
Data provider: ClinicalTrials.gov
Source updated: 2026-08-04
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:23:38 UTC

Documents

Study Protocol
Protocol2025-06-12

Locations

US(1)

Study Stopped

A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

SCLC

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Documents

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

SCLC

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Documents

Locations